Felix has been writing his own posts since the seed round closed. It worked, for a while. Then the product roadmap got heavier, the fundraising deck needed a rewrite, and content became the thing that slipped every single week.
Now he's staring at two paths: hire a writer, or bring in a specialist agency. Most advice on this decision is written for general B2B SaaS, and it skips the one variable that actually changes the math for digital health. The reader on the other end is often a clinician, and clinicians read differently than consumers do.
The decision arrives later than founders expect
Founders rarely plan this transition. It shows up as a symptom instead: a blog that hasn't published in six weeks, a founder-written LinkedIn post that ate three hours of a Tuesday, an investor update that recycled last quarter's language because there wasn't time to think fresh.
By the time Felix is weighing in-house against agency, he's usually already lost momentum he can't get back easily. That's worth naming up front, because it changes what "right" looks like. The fastest path back to publishing consistently usually beats the theoretically ideal org chart.
There's a second, quieter symptom too: the founder's own voice starts leaking out of the content. A rushed post written between two customer calls reads thinner than the one he wrote in his first month, even though he's learned more about the market since. That thinning is the real cost of the delay, not just the missed publishing dates.
What changes when the reader is a clinician
Most in-house-versus-agency comparisons assume a buyer who reads like anyone else on the internet: scanning, mildly skeptical, quick to bounce if the headline overpromises.
A clinician reads with a sharper filter. She's trained to spot an unsupported claim, and she's seen enough vendor blogs promise the world and cite nothing behind it. A sentence that passes fine in general B2B, something like "our platform improves patient outcomes," reads as unearned to her unless it's followed by a mechanism, a number, or a named source.
That filter changes what you're actually hiring for. You're not hiring someone who writes clean sentences. You're hiring someone who writes a clean sentence that also survives a clinician's instinct to ask "says who," on the first read, without her having to go looking for the evidence herself.
It also changes the review step. General B2B content gets checked for tone and grammar. Content aimed at a clinical reader needs a second layer: does this claim hold up, and is the source behind it real. Whoever writes for you needs to either carry that judgment themselves or work closely enough with someone who does.
The in-house writer, honestly
An in-house hire gives you three things an agency structurally can't: someone sitting in your Slack, someone who's heard the last ten sales calls, and someone who remembers last quarter's positioning fight without needing it re-explained.
That proximity matters more in digital health than in most categories. The angle for a piece often comes from something a clinical advisor said on a pilot call that morning, not from a keyword list sitting in a spreadsheet. A person embedded in the company catches that moment as it happens. A contractor who checks in twice a week usually catches it a week later, if at all.
The cost is real too, and founders tend to underestimate it. A writer who can handle clinical nuance and B2B strategy at the same time is a narrow hire. Narrow hires take months to find and cost more once found, and a single person, however sharp, has no second opinion on their own blind spots. If they misjudge a clinical claim, nobody catches it before it goes live. You've traded one bottleneck, you, for another, them.
The specialist agency, honestly
A specialist agency brings the opposite trade. You get a team that's already seen several versions of the clinical trust problem, so the learning curve is shorter than it is with a first-time solo hire. You get output that doesn't stop the week your one writer takes a two-week vacation, gets sick, or leaves for another job.
What you give up is proximity. An agency writer isn't in your Slack, isn't hearing the pilot call live, and needs the angle handed to them instead of absorbing it by osmosis. That's a real gap, and it's the one founders underestimate until the third or fourth piece comes back technically correct and strategically flat.
The fix isn't complicated, but it takes discipline on your side. A good agency relationship runs on a tight brief and a short feedback loop, not a "here's our website, go" handoff and radio silence for a month. Founders who treat the agency as an extension of their own thinking, feeding it the sales call notes and the advisor quotes as they happen, get work that reads like it came from inside the company. Founders who hand it off and disappear get generic B2B content with a health tech logo stapled on top.
What each option actually costs
Run the real numbers, not just the sticker price. A single in-house content hire in this space, someone who can genuinely handle clinical nuance, typically lands in a similar monthly range to a solid specialist agency retainer once you account for salary, benefits and the ramp time before they're producing at full speed.
The difference isn't mostly about price. It's about what happens in the gaps. A salaried hire keeps drawing pay during a slow publishing month and during the two weeks they're out sick. An agency retainer usually keeps producing regardless of who's out on their end, because the work doesn't sit with one irreplaceable person.
Neither structure is cheaper in a way that should decide this on its own. The deciding factor is what you're actually buying: dedicated attention with a single point of failure, or distributed capacity with a shorter institutional memory.
The test that actually predicts the right answer
Skip the pros-and-cons list for a minute and ask one question instead: who currently holds the angle in your company?
If it's you, and it's going to stay you for the next year because you're the clinician-turned-founder with the domain conviction nobody else has yet, an agency can work well. You supply the angle in a fifteen-minute call, they supply the execution and the volume, and the arrangement plays to what each side is actually good at.
If the angle needs to live inside someone's daily judgment, someone who's in the room when a clinical advisor pushes back on a feature claim, an in-house hire earns its cost faster. You're not paying for writing speed there. You're paying for someone who develops the same instinct you have, so the company doesn't lose its point of view the first month you get too busy to write it yourself.
Company stage matters here too, and it's less about headcount than about how settled your positioning is. Pre-Series A, while the story is still being tested against the market week to week, a close relationship, in-house or a genuinely embedded agency partner, beats a lower-touch vendor arrangement almost every time. Post-Series B, once the positioning has mostly settled and the job is largely execution at volume, the calculus shifts back toward whichever option scales more cheaply.
Four questions worth asking before you commit
Whichever way you're leaning, run it through these before you sign anything.
Can they name the difference between writing for your clinical champion and writing for your patient-facing audience, without you explaining it first? If the answer requires you to teach the distinction from scratch, you're not hiring expertise. You're hiring hands.
What happens to output the week something breaks? A launch slips, a key person is out, a deadline moves up. An agency with a bench usually answers this cleanly. A single in-house hire, however good, is a single point of failure, and that's worth planning around instead of discovering the hard way in month four.
How do they check a clinical claim before it publishes? "We're careful" isn't a process. A named source, a review step, or a stated standard for what needs a citation is a process. Ask for the actual mechanism, not the reassurance.
What does a bad first draft look like, and how fast does it improve by the third one? Ask for an example instead of a promise. The gap between draft one and draft three tells you more about whether this relationship will hold up than any pitch deck will.
Where PulseCopy fits, for what it's worth
We built PulseCopy around the middle ground this decision usually misses: the responsiveness founders want from an in-house hire, without the single point of failure, applied specifically to companies selling into clinical and health tech environments. We're not the right fit for every founder weighing this question, and the four questions above apply to us the same as they apply to anyone else you're evaluating.
If the angle test points you toward wanting a partner rather than a solo hire, that's a conversation worth having.
There's no universal right answer here
Founders searching this question usually want a clean verdict: hire, don't hire, agency wins, in-house wins. The honest answer depends on where your positioning still needs your daily judgment and where it's stable enough to hand to someone else's execution.
Get that one distinction right, and the in-house-versus-agency decision mostly makes itself.